2,2-Dideuterio-1,3-benzodioxole-5-sulfonyl chloride | 1256492-68-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 2,2-Dideuterio-1,3-benzodioxole-5-sulfonyl chloride
• 英文别名: 2,2-dideuterio-1,3-benzodioxole-5-sulfonyl chloride
• CAS: 1256492-68-8
• 化学式: C₇H₅ClO₄S
• 分子量: 222.617
• InChiKey: ICUBASIDCXDQAW-APZFVMQVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  61
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,2-Dideuterio-1,3-benzodioxole-5-sulfonyl chloride 在 对甲苯磺酸 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 4.83h， 生成 [(3aS,4R,6aR)-4,6a-dideuterio-2,3,3a,5-tetrahydrofuro[2,3-b]furan-4-yl] (4S,5R)-5-deuterio-5-[[(2,2-dideuterio-1,3-benzodioxol-5-yl)sulfonyl-[1,1,2,3,3,3-hexadeuterio-2-(trideuteriomethyl)propyl]amino]methyl]-2,2-dimethyl-4-[(4-phenylmethoxyphenyl)methyl]-1,3-oxazolidine-3-carboxylate
  参考文献：
  名称：

  Synthesis and pharmacokinetic profile of highly deuterated brecanavir analogs

  摘要：

  Several highly deuterated analogs of the HIV-1 protease inhibitor brecanavir have been prepared to study the effect of deuterium upon metabolic stability. The sites for deuterium incorporation were initially chosen to maximize the potential for a kinetic isotope effect; locations where C-H bond breaking is the rate limiting step. The analogs have been profiled in both in vitro and in vivo pharmacokinetic studies and the result will be described herein. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.02.001
• 作为产物：
  描述：

  Dideuterium benzo[d][1,3]dioxol 在 三氧化硫 N,N-二甲基甲酰胺络合物 、 草酰氯 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 20.0h， 生成 2,2-Dideuterio-1,3-benzodioxole-5-sulfonyl chloride
  参考文献：
  名称：

  Synthesis and pharmacokinetic profile of highly deuterated brecanavir analogs

  摘要：

  Several highly deuterated analogs of the HIV-1 protease inhibitor brecanavir have been prepared to study the effect of deuterium upon metabolic stability. The sites for deuterium incorporation were initially chosen to maximize the potential for a kinetic isotope effect; locations where C-H bond breaking is the rate limiting step. The analogs have been profiled in both in vitro and in vivo pharmacokinetic studies and the result will be described herein. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.02.001

文献信息

• COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
  申请人：FLATLEY DISCOVERY LAB

  公开号：US20140371238A1

  公开（公告）日：2014-12-18

  The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:

  本发明涉及一种I式化合物及治疗囊性纤维化的方法，包括向需要治疗的患者给予I式或IA式化合物的治疗有效剂量。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010135424A1

  公开（公告）日：2010-11-25

  The present invention relates to highly functionalized 1,3-diamino-propan-2-ols and pharmaceutically acceptable salts thereof. More specifically, the invention relates to highly functionalized 1,3-diamino-propan-2-ols that are derivatives of the HIV protease inhibitors brecanavir.
• Synthesis and pharmacokinetic profile of highly deuterated brecanavir analogs
  作者：Emile J. Velthuisen、Todd M. Baughman、Brian A. Johns、David P. Temelkoff、Jason G. Weatherhead

  DOI：10.1016/j.ejmech.2013.02.001

  日期：2013.5

  Several highly deuterated analogs of the HIV-1 protease inhibitor brecanavir have been prepared to study the effect of deuterium upon metabolic stability. The sites for deuterium incorporation were initially chosen to maximize the potential for a kinetic isotope effect; locations where C-H bond breaking is the rate limiting step. The analogs have been profiled in both in vitro and in vivo pharmacokinetic studies and the result will be described herein. (C) 2013 Elsevier Masson SAS. All rights reserved.